Arbutus Biopharma Corp
About
Arbutus Biopharma Corp (NASDAQ:ABUS) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 15 2026
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Mar 23 2026
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Mar 3 2026
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Nov 13 2025
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 7 2025
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Financials
Revenue
$14.08 M
Market Cap
$875.74 M
EPS
-0.17